Skip to Main Content

Author Details

Hal K Berman
Princess Margaret Cancer Centre, University Health Network
1997
51
27
PMIDPaper TitleJournal TitlePublished Year
37566240Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.Clin Cancer Res2023
37847590Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.Cell Rep2023
37695851Metabolic Lipids in Melanoma Enable Rapid Determination of Actionable BRAF-V600E Mutation with Picosecond Infrared Laser Mass Spectrometry in 10 s.Anal Chem2023
37883228Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.Cell Rep2023
35304464Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids.Nat Commun2022
35705312Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.J Immunother Cancer2022
35379580All is not lost: learning from 9p21 loss in cancer.Trends Immunol2022
35981243Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells.J Proteome Res2022
36395434Picosecond Infrared Laser Mass Spectrometry Identifies a Metabolite Array for 10 s Diagnosis of Select Skin Cancer Types: A Proof-of-Concept Feasibility Study.Anal Chem2022
34031589Mammary epithelial cells have lineage-rooted metabolic identities.Nat Metab2021
33529165RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.J Clin Invest2021
34446728Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.Nat Commun2021
34056539Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.JNCI Cancer Spectr2021
32094913Author Correction: Human somatic cell mutagenesis creates genetically tractable sarcomas.Nat Genet2020
30670564Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.J Clin Pathol2019
31741762Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer.Oncoimmunology2019
31267556Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention.EMBO J2019
29113931Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer.Neuroscience2018
35135130Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies.JCO Precis Oncol2018
29921600Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities.J Cell Biol2018
29514672The origins of breast cancer associated with mammographic density: a testable biological hypothesis.Breast Cancer Res2018
29177603Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.Breast Cancer Res Treat2018
28790030Notch Shapes the Innate Immunophenotype in Breast Cancer.Cancer Discov2017
28165478A distinct innate lymphoid cell population regulates tumor-associated T cells.Nat Med2017
27241552RANKL/RANK control Brca1 mutation- .Cell Res2016
27782854Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Genome Med2016
25527357B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.Cancer Immunol Res2015
25706237Expansion of stem cells counteracts age-related mammary regression in compound Timp1/Timp3 null mice.Nat Cell Biol2015
25620030Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.Cancer Cell2015
24336157Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.Mod Pathol2014
24662921Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.Cancer Res2014
23319603High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer.Proc Natl Acad Sci U S A2013
23857982BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.J Exp Med2013
22777768CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues.Cancer Discov2012
21199807Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.Cancer Res2011
22110626Spatial organization and correlations of cell nuclei in brain tumors.PLoS One2011
21920875p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.Cancer Prev Res (Phila)2011
20028875DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.Cancer Prev Res (Phila)2010
20427430Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.J Natl Cancer Inst2010
20424132Premalignant breast neoplasia: a paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications.Cancer Prev Res (Phila)2010
17563394Stratification of breast cancer risk in women with atypia: a Mayo cohort study.J Clin Oncol2007
17996651Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.Cancer Cell2007
15753376p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.Cancer Res2005
16869768Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis.Cold Spring Harb Symp Quant Biol2005
10683377Activation of direct and indirect pathways of glycogen synthesis by hepatic overexpression of protein targeting to glycogen.J Clin Invest2000
10862764Distinctive regulatory and metabolic properties of glycogen-targeting subunits of protein phosphatase-1 (PTG, GL, GM/RGl) expressed in hepatocytes.J Biol Chem2000
10998419Overexpression of protein targeting to glycogen in cultured human muscle cells stimulates glycogen synthesis independent of glycogen and glucose 6-phosphate levels.J Biol Chem2000
10448535Metabolic engineering with recombinant adenoviruses.Annu Rev Nutr1999
9756875Overexpression of protein targeting to glycogen (PTG) in rat hepatocytes causes profound activation of glycogen synthesis independent of normal hormone- and substrate-mediated regulatory mechanisms.J Biol Chem1998
9521775Fundamental metabolic differences between hepatocytes and islet beta-cells revealed by glucokinase overexpression.Biochemistry1998
  • 1 - 50 of 51

Recommended Authors

Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
University of Southern California
Career Start Year 2004
Number of shared co-authors 0
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2002
Number of shared co-authors 10
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 22
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 0
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 1
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 4
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 1
Baylor College of Medicine
Career Start Year 1996
Number of shared co-authors 1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 0
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 3
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 4
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 0
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 11
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 2
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 2
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 1
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 5
Washington University School of Medicine
Career Start Year 1987
Number of shared co-authors 3
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 2
Weill Medical College of Cornell University
Career Start Year 1984
Number of shared co-authors 4
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 1
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 4
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 1
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 5
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Princess Margaret Cancer Centre, University Health Network
Co-authored papers 11
Princess Margaret Cancer Centre, University Ave
Co-authored papers 8
Duke Molecular Physiology Institute
Co-authored papers 7
Princess Margaret Cancer Centre
Co-authored papers 7
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 6
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 6
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 5
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Princess Margaret Cancer Centre, University Avenue
Co-authored papers 4
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 3
University of Toronto.
Co-authored papers 3
Cancer Clinical Research Unit, Princess Margaret Cancer Centre
Co-authored papers 3
Max Planck Institute of Biochemistry
Co-authored papers 3
University Health Network
Co-authored papers 3
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 3
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 3
Toronto General Hospital, University Health Network, University of Toronto
Co-authored papers 3
Princess Margaret Cancer Centre/University Health Network
Co-authored papers 3
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Co-authored papers 2
University of Toronto, College Street
Co-authored papers 2
University Health Network
Co-authored papers 2
University of Ottawa
Co-authored papers 2
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Margaret Cancer Center
Co-authored papers 2
University Health Network
Co-authored papers 2